References

• Adler, A., Shaw, E., Stokes, T., & Ruiz, F. (2009). Newer agents for blood glucose control in type 2 diabetes: summary of NICE guid-ance. BMJ, 338, b1668-b1668. https://doi.org/10.1136/bmj.b1668 google scholar
• Athyros, V. G., Doumas, M., Imprialos, K. P., Stavropoulos, K., Geor-gianou, E., Katsimardou, A., & Karagiannis, A. (2018). Diabetes and lipid metabolism. Hormones (Athens, Greece), 17(1), 61-67. https:// doi.org/10.1007/s42000-018-0014-8 google scholar
• Bangert, S. (2008). Hyperlipidaemia: Diagnosis and Management (3rd edn.). Annals of Clinical Biochemistry, 45(6), 619-619. https:// doi.org/10.1258/acb.2008.200814 google scholar
• Berkowitz, S. A., Krumme, A. A., Avorn, J., Brennan, T., Matlin, O. S., Spettell, C. M., Pezalla, E. J., Brill, G., Shrank, W. H., & Choudhry, N. ,. (2014). Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA internal medicine, 174(12), 1955-1962. https://doi. org/10.1001/jamainternmed.2014.5294 google scholar
• Brunton, L., Lazo J, Buxton I, Blumenthal D, Akil H, Amrein P. (2005). Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill google scholar
• Busti, A. J. (2015). The Mechanism for Metformin’s (Glucophage) Im-provement in the Lipid Profile Beyond its Glucose Lowering Effects in Diabetes Mellitus. Ebmconsult.com. Retrieved 8 March 2018, from https://www.ebmconsult.com/articles/metformin-glucophage-diabetes-lipid-cholesterol-lowering. google scholar
• Chapman, M. J., Ginsberg, H. N., Amarenco, P,, Andreotti, F., Boren, J., et al European Atherosclerosis Society Consensus Panel. (2011). Triglyceride-rich lipoproteins and high-density lipoprotein cho-lesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal, 32(11), 1345-1361. https://doi.org/10.1093/eurheartj/ehr112 google scholar
• Chen, Y. H., Du, L., Geng, X. Y., Peng, Y. L., Shen, J. N., Zhang, Y. G., Liu, G. J., & Sun, X. (2015). Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled tri-als. Journal of Evidence-Based Medicine, 8(3), 134-148. https://doi. org/10.1111/jebm.12157 google scholar
• Davies, M., D’Alessio, D., Fradkin, J., Kernan, W., Mathieu, C., Min-grone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018). Management of hyperglycaemia in type 2 diabetes, 2018. A con-sensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Dia-betologia, 61(12), 2461-2498. https://doi.org/10.1007/s00125-018-4729-5 google scholar
• Dimitriadis, G., Mitrou, P., Lambadiari, V., Maratou, E., & Raptis, S. A. (2011). Insulin effects in muscle and adipose tissue. Diabetes Research and Clinical Practice, 93 Suppl 1, S52-S59. https://doi. org/10.1016/S0168-8227(11)70014-6 google scholar
• Florkowski C. (2013). HbA1c as a Diagnostic Test for Diabetes Mellitus - Reviewing the Evidence. The Clinical Biochemist. Re-views, 34(2), 75-83. google scholar
• Hussain, A., Ali, I., Ijaz, M., & Rahim, A. (2017). Correlation between hemoglobin A1c and serum lipid profile in Afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipid-emia. Therapeutic Advances in Endocrinology and Metabolism, 8(4), 51-57. https://doi.org/10.1177/2042018817692296 google scholar
• Indonesian Endocrinologist Association (PERKENI). (2015). The consensus in management and prevention of type 2 diabetes mellitus for 2015 Jakarta: Perkeni. https://pbperkeni.or.id/undu-han google scholar
• Jaiswal, M., Schinske, A., & Pop-Busui, R. (2014). Lipids and lipid management in diabetes. Best Practice & Research Clinical Endo-crinology & Metabolism, 28(3), 325-338. https://doi.org/10.1016/j. beem.2013.12.001 google scholar
• Kashi, Z., Mahrooz, A., Kianmehr, A., & Alizadeh, A. (2016). The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Met-formin. PloS one, 11(3), e0151543. https://doi.org/10.1371/journal. pone.0151543 google scholar
• Laisupasin, P., Thompat, W., Sukarayodhin, S., Sornprom, A., & Sudjaroen, Y. (2013). Comparison of Serum Lipid Profiles be-tween Normal Controls and Breast Cancer Patients. Journal of Laboratory Physicians, 5(1), 38-41. https://doi.org/10.4103/0974-2727.115934 google scholar
• Li, Y., Hu, Y., Ley, S. H., Rajpathak, S., & Hu, F. B. (2014). Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Dia-betes care, 37(11), 3106-3113. https://doi.org/10.2337/dc14-1306 Madsen, A., Bozickovic, O., Bjune, J.I., Mellgren. G., Sagen, J. V. (2015). Metformin inhibits hepatocellular glucose, lipid and cholesterol biosynthetic pathways by transcriptionally suppress-ing steroid receptor coactivator 2 (SRC-2). Sci Rep. doi: 10.1038/ srep16430. PMID: 26548416; PMCID: PMC4637908. google scholar
• Middleton, T. L., Wong, J., Molyneaux, L., Brooks, B. A., Yue, D. K., Twigg, S. M., & Wu, T. (2017). Cardiac Effects of Sulfonylurea-Re-lated Hypoglycemia. Diabetes Care, 40(5), 663-670. https://doi. org/10.2337/dc16-1972 google scholar
• Ministry of Health. (2013). Basic Health Research 2013. Jakarta: Ministry of Health Republic of Indonesia. https://www.litbang. kemkes.go.id/laporan-riset-kesehatan-dasar-riskesdas/ google scholar
• Natali, A., & Ferrannini, E. (2006). Effects of metformin and thia-zolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a system-atic review. Diabetologia, 49(3), 434-441. https://doi.org/10.1007/ s00125-006-0141-7 google scholar
• Nuttall, F. Q. (2015). Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutrition today, 50 (3), 117-128. https://doi. org/10.1097/NT.0000000000000092 google scholar
• Rao, A. D., Kuhadiya, N., Reynolds, K., & Fonseca, V. A. (2008). Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care, 31(8), 16721678. https://doi.org/10.2337/dc08-0167 google scholar
• Sauriasari, R., Andriany, R., Sekar, A., & Azizahwati, A. (2017). Com-parison of Antioxidative Effect of Metformin and Combination of Metformin-Sulfonylurea in Type 2 Diabetes Mellitus Patients. Journal of Young Pharmacists, 9(1), 39-42. https://doi.org/10.5530/ jyp.2017.1s.10 google scholar
• Sauriasari, R., Aristia H., Azizahwati (2020). Urine albumin-to-cre-atinine ratio and estimated glomerular filtration rate in matched groups of type 2 diabetes mellitus patients receiving metformin and metformin-sulfonylurea. International Journal of Applied Phar-maceutics. 12(Special Issue I), 257-259. DOI: 10.22159/ijap.2020. v12s1.FF056 google scholar
• Schofield, J. D., Liu, Y., Rao-Balakrishna, P., Malik, R. A., & Soran, H. (2016). Diabetes Dyslipidemia. Diabetes therapy: research, treat-ment and education of diabetes and related disorders, 7(2), 203219. https://doi.org/10.1007/s13300-016-0167-x google scholar
• Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., De-pinho, R. A., Montminy, M., & Cantley, L. C. (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (New York, N.Y.), 310(5754), 1642-1646. https:// doi.org/10.1126/science.1120781 google scholar
• Sola, D., Rossi, L., Schianca, G., Maffioli, P., Bigliocca, M., & Mella, R. et al. (2015). State of the art paper Sulfonylureas and their use in clinical practice. Archives Of Medical Science, 4, 840-848. https:// doi.org/10.5114/aoms.2015.53304 google scholar
• Tsimihodimos, V., Gonzalez-Villalpando, C., Meigs, J., & Ferrannini, E. (2018). Hypertension and Diabetes Mellitus. Hypertension, 71(3), 422-428. https://doi.org/10.1161/hypertensionaha.117.10546 google scholar
• WHO. Diabetes. Who.int. (2021). Retrieved 10 November 2021, from http://www.who.int/news-room/fact-sheets/detail/diabe-tes. google scholar
• Zhang, F., Xiang, H., Fan, Y., Ganchuluun, T. A., Kong, W., Ouyang, Q., Sun, J., Cao, B., Jiang, H., & Nie, S. (2013). The effects of sulfo-nylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized con-trolled trials. Endocrine, 44(3), 648-658. https://doi.org/10.1007/ s12020-013-9970-6 google scholar
• Zhang, X., Song, Y., Feng, M., Zhou, X., Lu, Y., Gao, L., Yu, C., Jiang, X., & Zhao, J. (2015). Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP-activated protein kinase in the liver. Journal of Lipid Research, 56(5), 963-971. https://doi. org/10.1194/jlr.M047654 google scholar

Citations